Overview

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer.

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive unresectable locally advanced or metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Miracogen Inc.